The robust Phase 2 data and Blackstone financing significantly de-risk zumilokibart's path to market. Traders should watch for regulatory interactions and Phase 3 initiation in 2H 2026. The pipeline-in-a-product potential (asthma, EoE) adds upside optionality. Monitor upcoming 52-week Part B data and any partnership/out-licensing news.
Price Chart
Executive Summary
Apogee Therapeutics announced positive 16-week Phase 2 APEX Part B data for zumilokibart in moderate-to-severe atopic dermatitis, meeting primary and secondary endpoints with high statistical significance. The mid-dose achieved 65.9% EASI-75 (41.9% placebo-adjusted) and a favorable safety profile, supporting advancement into Phase 3 trials in 2H 2026. A strategic financing collaboration with Blackstone Life Sciences was also announced, expected to fund through commercialization.
Key Facts
- Phase 2 APEX Part B met primary endpoint: mid-dose zumilokibart achieved 65.9% EASI-75 vs 23.4% placebo (p<0.001).
- Key secondary endpoints met: IGA 0/1 46.0% vs 10.9%, EASI-90 47.4% vs 9.3%, I-NRS ≥4 50.5% vs 13.9% (all p<0.001).
- Very Low Disease Activity (vLDA) achieved in 20.6% of mid-dose patients vs 4.5% placebo (p<0.01).
- Safety profile consistent with class; conjunctivitis rate for mid-dose was 10.6% vs 20.7% for high dose.
- Company plans to initiate Phase 3 ADventure trials in AD in 2H 2026, Phase 2b ASPIRE in asthma in 1H 2027, and Phase 2a ELEVATE in EoE in 2H 2026.
- Strategic financing collaboration with Blackstone Life Sciences announced to fund through commercialization.
- Mid-dose selected for Phase 3 based on best clinical activity and tolerability.
Financial Impact
Not disclosed; financing collaboration with Blackstone Life Sciences expected to fund through commercialization of zumilokibart in AD, asthma, and EoE.
Risk Factors
- Phase 3 trials may fail to replicate Phase 2 efficacy or safety results.
- Regulatory interactions could delay or alter Phase 3 trial design.
- Competition from existing IL-13/IL-4Rα biologics (e.g., dupilumab) and emerging therapies.
- Dependence on Blackstone financing terms and potential dilution if additional capital needed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301719 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 15-12G | — | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | 25-NSE | $135.06 awaiting T+5 | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | 8-K | $135.06 awaiting T+5 | awaiting T+5 | — | — |
Aug 11, 2026 7w ago | 8-K | $134.55 $134.71 | ▲ +0.12% | ▲ +0.56% | — |
Aug 10, 2026 7w ago | 8-K | $134.65 $134.59 | ▼ −0.04% | ▲ +0.00% | — |
Aug 10, 2026 7w ago | Press Release | $134.65 $134.59 | ▼ −0.04% | ▲ +0.00% | — |
Aug 6, 2026 8w ago | Institutional Cluster | $134.49 $134.45 | ▼ −0.03% | ▼ −1.24% | — |
Aug 3, 2026 8w ago | DEFA14A | $134.19 $134.69 | ▲ +0.37% | ▲ +0.47% | — |
Jul 11, 2026 11w ago | Insider Cluster | $133.82 $134.00 | ▲ +0.13% | ▲ +0.92% | — |
Jun 26, 2026 13w ago | DEFA14A | $132.61 $133.50 | ▲ +0.67% | ▼ −0.72% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access